Compare Southwest Airlines Co (LUV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs GeneDx Holdings Corp — how do they compare? Southwest Airlines Co trades at $41.71 (market cap $20.23B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Southwest Airlines Co is far larger — about 10× GeneDx Holdings Corp's market cap, and Southwest Airlines Co pays a 1.74% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and GeneDx Holdings Corp for 19 Days on average.
| LUV | WGS | |
|---|---|---|
Market Cap | $20.23B | $2.02B |
Volume | 14,560,422 | 734,640 |
Sector | Industrials | Health |
52-Week High | $54.80 | $167.51 |
52-Week Low | $29.67 | $34.51 |
Typical Hold Time | 65 Days | 19 Days |
Enterprise Value | $23.33B | $2.05B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.66, down 0.14% with a bearish technical signal. The stock shows mixed earnings performance with a recent Q2 beat but Q1 miss. Valuation metrics appear reasonable with P/E of 25.85 and P/S of 0.72. The company is undergoing a commercial transformation with new fare structures expected to generate significant EBIT growth, though net margins remain thin at 2.78%. Cash flow trends show improvement projected for 2026 with positive net cash flow of $316M.
LUV presents a turnaround opportunity with its revenue transformation initiatives targeting over $2 billion EBIT in 2026. The 19% upside to consensus price target of $49.61 offers potential reward, but risks include high fuel costs, competitive pressure from legacy carriers, and execution challenges. Analyst sentiment is mixed with 42% buy ratings amid ongoing operational changes.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
